The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: The amotosalen-ultraviolet A pathogen reduction treatment model

Transfusion

Volumn 56, Issue , 2016, Pages S29-S38

  Weiskopf, Richard B ^a   Corash, Laurence ^a   Benjamin, Richard J ^a  

^a CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; FUROCOUMARIN DERIVATIVE;

ACUTE LUNG INJURY; ALLERGIC REACTION; ARTICLE; BACTERIAL INFECTION; BLOOD SAFETY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL EFFECTIVENESS; EUROPE; FRANCE; GAMMA IRRADIATION; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; NONHUMAN; PLASMA TRANSFUSION; POSTMARKETING SURVEILLANCE; REGISTRATION; SCREENING; SWITZERLAND; THROMBOCYTE TRANSFUSION; TRANSFUSION MEDICINE; ULTRAVIOLET A RADIATION; CHEMISTRY; DISINFECTION; PROCEDURES; THEORETICAL MODEL; ULTRAVIOLET RADIATION;

BLOOD SAFETY; DISINFECTION; FUROCOUMARINS; HUMANS; MODELS, THEORETICAL; PRODUCT SURVEILLANCE, POSTMARKETING; ULTRAVIOLET RAYS;

EID: 84961775109     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13530     Document Type: Article

References (32)

1. Klein HG, Anderson D, Bernardi MJ, et al., Pathogen inactivation: making decisions about new technologies: report of a consensus conference. Transfusion 2007; 47: 2338-47.
2. McCullough J, Vesole DH, Benjamin RJ, et al., Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104: 1534-41.
3. Andreu G, Morel P, Forestier F, et al., Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994-1998. Transfusion 2002; 42: 1356-64.
4. Cerus Corporation. An open label, post marketing surveillance study following transfusion of INTERCEPT platelet components (PIPER). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015-[cited 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT02549222 NLM Identifier: NCT02549222.
5. Bell CE, Botteman MF, Gao X, et al., Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003; 25: 2464-86.
6. McCullough J, Goldfinger D, Gorlin J, et al., Cost implications of implementation of pathogen-inactivated platelets. Transfusion 2015; 55: 2312-20.
7. Cerus Corporation. INTERCEPT blood system for platelets [Internet]. Concord (CA): Cerus Corporation; 2015. Available from: http://www.intercept-usa.com/images/resources/files/INTERCEPT-Blood-System-Platelet-Package-Insert.pdf.
8. Cerus Corporation. INTERCEPT blood system for plasma [Internet]. Concord (CA): Cerus Corporation; 2015. Available from: http://www.intercept-usa.com/images/resources/files/INTERCEPT-Blood-System-Plasma-Package-Insert.pdf.
9. van Rhenen DJ, Gulliksson H, Cazenave JP, et al., Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
10. Osselaer JC, Messe N, Hervig T, et al., A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-71.
11. Knutson F, Osselaer J, Pierelli L, et al., A prospective, active hemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015; 109: 343-52.
12. Osselaer JC, Cazenave JP, Lambermont M, et al., An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-23.
13. Cazenave JP, Waller C, Kientz D, et al., An active hemovigilance program characterizing the safety profile of 7,483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50: 1210-9.
14. Brouard C, Bernillon P, Quatresous I, et al., Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008; 48: 1333-41.
15. Rasonglès P, Angelini-Tibert MF, Simon P, et al., Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009; 49: 1083-91.
16. Cazenave JP, Isola H, Waller C, et al., Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-9.
17. Ozier Y, Muller JY, Mertes PM, et al., Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion 2011; 51: 2102-10.
18. Kleinman S, Caulfield T, Chan P, et al., Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44: 1774-89.
19. Toy P, Gajic O, Bacchetti P, et al., Transfusion related acute lung injury: incidence and risk factors. Blood 2011; 119: 1757-67.
20. Dewachter P, Castro S, Nicaise-Roland P, et al., Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 2011; 106: 687-9.
21. Nubret K, Delhoume M, Orsel I, et al., Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 2011; 51: 125-8.
22. Corash L, Lin JS, Sherman CD, et al., Determination of acute lung injury after repeated platelet transfusions. Blood 2011; 117: 1014-20.
23. Jutzi M, Amsler L., Haemovigilance annual report 2013. Bern (Switzerland): Swissmedic; 2014.
24. Hong H, Xiao W, Lazarus HM, et al., Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood 2015. doi: 10.1182/blood-2015-07655944. [Epub ahead of print].
25. Osselaer JC, Doyen C, Defoin L, et al., Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49: 1412-22.
26. Cazenave JP, Isola H, Kientz D., Pathogen inactivation of platelets. In:, Sweeney J, Lozano M, editors. Platelet transfusion therapy. Bethesda (MD): AABB Press; 2013. p. 119-76.
27. Cinqualbre J, Kientz D, Remy E, et al., Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation. Transfusion 2015; 55: 1710-20.
28. Herbrecht R, Ojeda-Uribe M, Cazenave JP, et al., Comparative effectiveness of plasma prepared with pathogen inactivation (PI) (amotosalen-UVA) and quarantine for treatment of acquired immune thrombotic thrombocytopenic purpura (TTP) [abstract]. Transfusion 2013; 53: 121A.
29. Bartelmaos T, Chabanel A, Léger J, et al., Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013; 53: 1335-45.
30. Blood Products Advisory Committee. Safety and efficacy of OctaplasLG, solvent/detergent, ligand gel affinity chromatography treated plasma. Rockville (MD): Center for Biologics Evaluation and Research, US FDA; 2012.
31. Benhamou Y, Boelle PY, Baudin B, et al., Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 2015; 13: 293-302.
32. Lin L, Conlan MG, Tessman J, et al., Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005; 45: 1610-20.